73 related articles for article (PubMed ID: 25738885)
41. The cytotoxic mechanisms of disulfiram and copper(ii) in cancer cells.
Tawari PE; Wang Z; Najlah M; Tsang CW; Kannappan V; Liu P; McConville C; He B; Armesilla AL; Wang W
Toxicol Res (Camb); 2015 Nov; 4(6):1439-1442. PubMed ID: 27708770
[TBL] [Abstract][Full Text] [Related]
42. Open access to breast tumours.
Bradbury J
Lancet Oncol; 2006 Mar; 7(3):197. PubMed ID: 16538778
[No Abstract] [Full Text] [Related]
43. Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer.
Allensworth JL; Evans MK; Bertucci F; Aldrich AJ; Festa RA; Finetti P; Ueno NT; Safi R; McDonnell DP; Thiele DJ; Van Laere S; Devi GR
Mol Oncol; 2015 Jun; 9(6):1155-68. PubMed ID: 25769405
[TBL] [Abstract][Full Text] [Related]
44. Disulfiram/copper-disulfiram Damages Multiple Protein Degradation and Turnover Pathways and Cytotoxicity is Enhanced by Metformin in Oesophageal Squamous Cell Carcinoma Cell Lines.
Jivan R; Damelin LH; Birkhead M; Rousseau AL; Veale RB; Mavri-Damelin D
J Cell Biochem; 2015 Oct; 116(10):2334-43. PubMed ID: 25846272
[TBL] [Abstract][Full Text] [Related]
45. A phase IIb trial assessing the addition of disulfiram to chemotherapy for the treatment of metastatic non-small cell lung cancer.
Nechushtan H; Hamamreh Y; Nidal S; Gotfried M; Baron A; Shalev YI; Nisman B; Peretz T; Peylan-Ramu N
Oncologist; 2015 Apr; 20(4):366-7. PubMed ID: 25777347
[TBL] [Abstract][Full Text] [Related]
46. Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation.
Qin JJ; Wang W; Voruganti S; Wang H; Zhang WD; Zhang R
Oncotarget; 2015 Feb; 6(5):2623-40. PubMed ID: 25739118
[TBL] [Abstract][Full Text] [Related]
47. Disulfiram inhibits TGF-β-induced epithelial-mesenchymal transition and stem-like features in breast cancer via ERK/NF-κB/Snail pathway.
Han D; Wu G; Chang C; Zhu F; Xiao Y; Li Q; Zhang T; Zhang L
Oncotarget; 2015 Dec; 6(38):40907-19. PubMed ID: 26517513
[TBL] [Abstract][Full Text] [Related]
48. Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo.
Huang H; Liao Y; Liu N; Hua X; Cai J; Yang C; Long H; Zhao C; Chen X; Lan X; Zang D; Wu J; Li X; Shi X; Wang X; Liu J
Oncotarget; 2016 Jan; 7(3):2796-808. PubMed ID: 26625200
[TBL] [Abstract][Full Text] [Related]
49. Disulfiram and its novel derivative sensitize prostate cancer cells to the growth regulatory mechanisms of the cell by re-expressing the epigenetically repressed tumor suppressor-estrogen receptor β.
Sharma V; Verma V; Lal N; Yadav SK; Sarkar S; Mandalapu D; Porwal K; Rawat T; Maikhuri JP; Rajender S; Sharma VL; Gupta G
Mol Carcinog; 2016 Nov; 55(11):1843-1857. PubMed ID: 26599461
[TBL] [Abstract][Full Text] [Related]
50. Disulfiram anti-cancer efficacy without copper overload is enhanced by extracellular H2O2 generation: antagonism by tetrathiomolybdate.
Calderon-Aparicio A; Strasberg-Rieber M; Rieber M
Oncotarget; 2015 Oct; 6(30):29771-81. PubMed ID: 26356671
[TBL] [Abstract][Full Text] [Related]
51. Disulfiram sensitizes pituitary adenoma cells to temozolomide by regulating O6-methylguanine-DNA methyltransferase expression.
Zhao Y; Xiao Z; Chen W; Yang J; Li T; Fan B
Mol Med Rep; 2015 Aug; 12(2):2313-22. PubMed ID: 25937029
[TBL] [Abstract][Full Text] [Related]
52. Advancing Cancer Therapy with Copper/Disulfiram Nanomedicines and Drug Delivery Systems.
Kang X; Jadhav S; Annaji M; Huang CH; Amin R; Shen J; Ashby CR; Tiwari AK; Babu RJ; Chen P
Pharmaceutics; 2023 May; 15(6):. PubMed ID: 37376016
[TBL] [Abstract][Full Text] [Related]
53. A comparative study of smart nanoformulations of diethyldithiocarbamate with Cu
Abu-Serie MM; Abdelfattah EZA
Sci Rep; 2023 Mar; 13(1):3529. PubMed ID: 36864097
[TBL] [Abstract][Full Text] [Related]
54. The repositioned drugs disulfiram/diethyldithiocarbamate combined to benznidazole: Searching for Chagas disease selective therapy, preventing toxicity and drug resistance.
Almeida-Silva J; Menezes DS; Fernandes JMP; Almeida MC; Vasco-Dos-Santos DR; Saraiva RM; Viçosa AL; Perez SAC; Andrade SG; Suarez-Fontes AM; Vannier-Santos MA
Front Cell Infect Microbiol; 2022; 12():926699. PubMed ID: 35967878
[TBL] [Abstract][Full Text] [Related]
55. Recent advances in the delivery of disulfiram: a critical analysis of promising approaches to improve its pharmacokinetic profile and anticancer efficacy.
Farooq MA; Aquib M; Khan DH; Hussain Z; Ahsan A; Baig MMFA; Wande DP; Ahmad MM; Ahsan HM; Jiajie J; Wang B
Daru; 2019 Dec; 27(2):853-862. PubMed ID: 31758497
[TBL] [Abstract][Full Text] [Related]
56. Recent Advances in Antabuse (Disulfiram): The Importance of its Metal-binding Ability to its Anticancer Activity.
Viola-Rhenals M; Patel KR; Jaimes-Santamaria L; Wu G; Liu J; Dou QP
Curr Med Chem; 2018 Feb; 25(4):506-524. PubMed ID: 29065820
[TBL] [Abstract][Full Text] [Related]
57. Use of the disulfiram/copper complex for breast cancer chemoprevention in MMTV-erbB2 transgenic mice.
Yang Y; Deng Q; Feng X; Sun J
Mol Med Rep; 2015 Jul; 12(1):746-52. PubMed ID: 25738885
[TBL] [Abstract][Full Text] [Related]
58. Curcumin induces apoptosis in breast cancer cell lines and delays the growth of mammary tumors in neu transgenic mice.
Masuelli L; Benvenuto M; Fantini M; Marzocchella L; Sacchetti P; Di Stefano E; Tresoldi I; Izzi V; Bernardini R; Palumbo C; Mattei M; Lista F; Galvano F; Modesti A; Bei R
J Biol Regul Homeost Agents; 2013; 27(1):105-19. PubMed ID: 23489691
[TBL] [Abstract][Full Text] [Related]
59. Buformin inhibits the stemness of erbB-2-overexpressing breast cancer cells and premalignant mammary tissues of MMTV-erbB-2 transgenic mice.
Parris AB; Zhao Q; Howard EW; Zhao M; Ma Z; Yang X
J Exp Clin Cancer Res; 2017 Feb; 36(1):28. PubMed ID: 28193239
[TBL] [Abstract][Full Text] [Related]
60. Effect of annatto-tocotrienols supplementation on the development of mammary tumors in HER-2/neu transgenic mice.
Pierpaoli E; Viola V; Barucca A; Orlando F; Galli F; Provinciali M
Carcinogenesis; 2013 Jun; 34(6):1352-60. PubMed ID: 23430951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
